Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

Denosumab and new-onset degenerative arthritis in patients with osteoporosis

Association between denosumab use and risk of osteoarthritis among adults with osteoporosis in a real-world cohort

Osteoarthritis and Cartilage

Citation & Authors

Osteoarthritis Cartilage. 2026;34(8):1270–1280.

Zhaohua Zhu; Jing-Yang Huang; Weishu Wang; Sisi Liu; Hao Zhang; Qian Wang; Kai Fu; Changhai Ding; James Cheng-Chung Wei; David J Hunter

ABSTRACT · RESEARCH SUMMARY

Research summary

This new-user, active-comparator study matched 59,157 pairs of denosumab and bisphosphonate users. Denosumab was associated with a lower risk of knee osteoarthritis (HR 0.87; 95% CI 0.84–0.91), with no significant differences for hip or thumb carpometacarpal osteoarthritis. This is an observational association following treatment selection; clinical trials are needed to establish whether knee OA can be prevented.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗

Key findings

After matching, each group included 59,157 patients. Compared with bisphosphonates, denosumab was associated with a lower risk of incident knee osteoarthritis (HR 0.87; 95% CI 0.84–0.91), but hip osteoarthritis did not differ significantly (HR 0.98; 95% CI 0.94–1.03).

Findings differed between the knee and hip. This observational study does not establish that denosumab prevents or treats osteoarthritis; confirmation in clinical trials is needed.